Andrew E. Tee
Sydney, NSW, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Correction: Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 11, 2026
Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 03, 2020
The RNA-helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma.
Journal: Molecular oncology
Published: April 21, 2020
Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Journal: International journal of cancer
Published: May 07, 2019
The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35.
Journal: Nature communications
Published: November 13, 2018
The histone chaperone complex FACT promotes proliferative switch of G0 cancer cells.
Journal: International journal of cancer
Published: June 06, 2018
JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma.
Journal: Nature communications
Published: April 27, 2018
Upregulation of LYAR induces neuroblastoma cell proliferation and survival.
Journal: Cell death and differentiation
Published: November 30, 2016
NCYM is upregulated by lncUSMycN and modulates N-Myc expression.
Journal: International journal of oncology
Published: August 08, 2016
The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.
Journal: Oncotarget
Published: June 06, 2016
Last Updated: 09/26/2026